In vitro and in vivo chemoresistance analyses confirmed that MTDH knockdown sensitizes various types of tumors — including breast cancer, hepatocellular carcinoma, prostate cancer, and neuroblastoma— to multiple chemotherapy agents such as 5-fluorouracil (5-FU), cisplatin, paclitaxel, and doxorubicin [1], [10], [11]. This evidence concerns the gene MTDH and prostate cancer.